
Opinion|Videos|April 30, 2025
Examining The Pathophysiology Of Bronchiectasis
Panelists discusses how the "vicious vortex model" explains bronchiectasis pathophysiology, where airway dilatation leads to mucus stagnation, chronic infections, and neutrophilic inflammation, worsening the condition.
Advertisement
Episodes in this series

Clinical Brief: Understanding Bronchiectasis Pathophysiology
Main Discussion Topics
- Symptoms of bronchiectasis include cough, sputum production, and shortness of breath, similar to other respiratory diseases but with distinguishing features
- Bronchiectasis involves irreversible, dilated airways visible on imaging, unlike asthma (which is more reversible) and COPD (which presents with emphysema)
- Diagnostic differentiation between bronchiectasis, asthma, and COPD is important despite symptom overlap
Key Points for Physicians
- Patients with bronchiectasis typically present with more copious mucus production and recurrent infections
- On imaging, bronchiectasis appears as irreversibly dilated airways
- COPD typically presents with emphysema (destroyed alveolar areas) on imaging
- Asthma has day-to-day or diurnal variability and is generally more reversible
Notable Insights
Bronchiectasis is structurally distinct from both asthma and COPD despite sharing similar respiratory symptoms, making accurate diagnosis crucial for appropriate management.
Clinical Significance
Understanding the pathophysiological differences between bronchiectasis, asthma, and COPD is essential for accurate diagnosis and targeted management strategies.
Advertisement
Related to this article

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5

